Better Therapeutics names new chief commercial officer

BT-001 [Image from Better Therapeutics website]Better Therapeutics (Nasdaq:BTTX) announced today that it appointed Diane Gomez-Thinnes as its new chief commercial officer (CCO).

Gomez-Thinnes’ appointment became effective yesterday, Oct. 26, 2022. She joins the San Francisco-based company, which develops prescription digital therapeutics (PDTs). They use a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, including diabetes. The company last month submitted its BT-001 digital therapeutic for type 2 diabetes to the FDA for de novo classification.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

7 innovative digital health offerings to treat diabetes

MIT engineers are working on an app that that identifies and quantifies food content, which can aid in carbohydrate counting for people with diabetes. [Image from MIT News] From using your smartphone to track data to reversing your diabetes altogether, these digital health technologies stand out.

Advances in treatments for diabetes never stop coming. Whether that be in the form of insulin pumps or continuous glucose monitors, we’ve seen plenty.

Moving away from the physical device, innovations in the digital diabetes space continue to impress. Digital therapeutics, artificial intelligence- and cloud-based offerings and more comprise an intriguing list of technologies.

Here are seven digital offerings aimed at treating diabetes that you might want to keep an eye on:

1. Digital therapeutics for diabetes

Digital therapeutics is an ever-growing space capable of treating a range of diseases and conditions. That reach extends to diabetes, as shown by companies…

Read more
  • 0

Better Therapeutics submits FDA de novo request for type 2 diabetes treatment

Better Therapeutics (Nasdaq:BTTX) announced today that it submitted a de novo classification request to the FDA for its BT-001 technology.

San Francisco-based Better Therapeutics seeks marketing authorization for the BT-001 prescription digital therapeutic (PDT). It potentially represents the first-in-class PDT using cognitive behavioral therapy (CBT) to treat type 2 diabetes. Marketing initially would cover type 2 diabetes patients aged 18 years and older.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

The biggest medtech personnel moves so far in 2022

In the ever-changing world of medtech, those who are leading the companies are bound to move around a bit.

At the end of last year, we compiled a list of medtech’s biggest personnel changes in 2021. Throughout just over half of 2022, we’ve already seen a slew of major moves around some of the space’s most powerful players.

Here is a list of some of the biggest personnel changes in medtech so far in 2022:

3M’s healthcare president retires 3M Health Care Business Group President Mojdeh Poul [Image courtesy of 3M]Mojdeh Poul, the president of 3M’s healthcare business, announced in May that she would retire from the position and her retirement was made effective on July 1.

Poul joined 3M in 2011 as the global business VP of critical and chronic care solutions. She later became VP and general manager of the company’s food safety business and president of numerous 3M divisions, including infection prevention, 3M Canada, and sa…

Read more
  • 0

Digital therapeutics developer Better Therapeutics names new CEO

Better Therapeutics (Nasdaq:BTTX) announced today that it appointed Frank Karbe as its new president and CEO.

San Francisco-based Better Therapeutics develops prescription digital therapeutics (PDTs) based on nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Digital therapeutics open up new opportunities in medicine

Pear Therapeutics designed the reSET prescription digital therapeutic for the treatment of substance abuse disorder. [Image courtesy of Pear Therapeutics]A wide range of companies are aiming to make waves through digital therapeutic offerings, and each is doing things differently.

“We are seeing tremendous momentum for the DTx industry, with more and more products coming to market and gaining commercial coverage and recent signals from the White House and Congress demonstrating their interest and recognition of DTx products as an important way to expand access to quality treatments for populations with public coverage, especially underserved communities,” Digital Therapeutics Alliance CEO Andy Molnar said via email. “While we are riding a massive swell, the wave hasn’t even begun to crest. The community is expanding and convening this broad coalition of stakeholders is critical to really scale the industry and drive DTx adoption and integration to truly transform healthc…

Read more
  • 0

Digital therapeutics open up new opportunities in medical design

A wide range of companies are aiming to make waves through digital therapeutic offerings and each is doing things differently.

“We are seeing tremendous momentum for the DTx industry, with more and more products coming to market and gaining commercial coverage and recent signals from the White House and Congress demonstrating their interest and recognition of DTx products as an important way to expand access to quality treatments for populations with public coverage, especially underserved communities,” Digital Therapeutics Alliance CEO Andy Molnar told Medical Design & Outsourcing. “While we are riding a massive swell, the wave hasn’t even begun to crest. The community is expanding and convening this broad coalition of stakeholders is critical to really scale the industry and drive DTx adoption and integration to truly transform healthcare.” 

Read: How DeepWell is developing video games as tools for treating me…

Read more
  • 0

Better Therapeutics reaches key milestones for prescription digital therapeutics

Better Therapeutics (Nasdaq:BTTX) announced today that it hit multiple key research milestones as it validates its digital therapeutics.

San Francisco-based Better Therapeutics develops prescription digital therapeutics designed to deliver a novel form of cognitive-behavioral therapy for treating cardiometabolic diseases, potentially improving key measures related to type 2 diabetes, hypertension and more.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Better Therapeutics completes enrollment in type 2 diabetes study

Better Therapeutics (NSDQ:BTTX) announced that it completed patient enrollment in a study of its digital therapeutic in treating diabetes.

San Francisco-based Better Therapeutics’ BT-001 prescription digital therapeutic delivers a novel form of cognitive-behavioral therapy to patients with uncontrolled type 2 diabetes.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Better Therapeutics closes SPAC merger, debuts on Nasdaq

Better Therapeutics announced today that it completed its merger with Mountain Crest Acquisition Corp and has gone public on the Nasdaq.

San Francisco-based Better Therapeutics announced its intention to merge with Mountain Crest, a publicly-traded, special purpose acquisition corporation (SPAC), in April. Last month, the company confirmed its expectations for the $113 million SPAC merger to go through by the end of October, as it has today.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Better Therapeutics expects $113M SPAC merger to go through in October

Better Therapeutics announced today that it expects its merger with Mountain Crest Acquisition Corp to close next month.

San Francisco-based Better Therapeutics announced its intention to merge with Mountain Crest, a publicly-traded, special purpose acquisition corporation (SPAC), in April. At the time of the announcement, the companies expected the merger to be completed some time in the summer of 2021.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Better Therapeutics secures $50M debt facility for digital diabetes treatment tech

Better Therapeutics announced today that it secured a loan debt facility worth up to $50 million from Hercules Capital.

The debt facility provides up to $150 million in total financing when combined with the proceeds from going public through a $113 million merger with SPAC Mountain Crest Acquisition Corp II and a PIPE investment.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0